Holen Sie sich die Stockscreener-App
1.20
0.41%
-0.005
Handel nachbörslich:
1.25
0.05
+4.17%
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September - GlobeNewswire
One-Year Clinical Data: Opus Genetics' Revolutionary Gene Therapy for Inherited Retinal Disease at Global Forums - Stock Titan
What does recent volatility data suggest for Opus Genetics Inc.2025 Historical Comparison & Stepwise Trade Signal Implementation - Newser
Visualizing Opus Genetics Inc. stock with heatmapsAnalyst Upgrade & Verified Swing Trading Watchlists - Newser
Opus Genetics Inc. stock outlook for YEAR2025 Price Targets & Expert Curated Trade Setup Alerts - Newser
Can Opus Genetics Inc. rally from current levelsCEO Change & Entry Point Confirmation Signals - Newser
Opus Genetics completes $3.5 million private placement of common stock By Investing.com - Investing.com Australia
Opus Genetics: A Strategic Capital Raise Fuels Gene Therapy Ambitions in Inherited Retinal Diseases - AInvest
Opus Genetics Inc enters agreements for private placement of shares - MarketScreener
Is Opus Genetics Inc. still a buy after recent gainsCPI Data & Weekly High Return Forecasts - theviewers.co.kr
Is Opus Genetics Inc. trending in predictive chart models2025 Market WrapUp & Weekly High Return Stock Forecasts - Newser
Market Overview: Is Opus Genetics Inc. benefiting from innovation trendsTrade Analysis Report & Target Return Focused Picks - theviewers.co.kr
Will Opus Genetics Inc. outperform the marketJuly 2025 Movers & Technical Pattern Based Buy Signals - Newser
Using flow based indicators on Opus Genetics Inc.Weekly Market Report & Daily Chart Pattern Signals - Newser
Can Opus Genetics Inc. expand its profit marginsJuly 2025 WrapUp & AI Enhanced Trade Execution Alerts - sundaytimes.kr
Are Bears Losing Grip on Opus Genetics Inc.July 2025 Movers & Free Reliable Trade Execution Plans - kangso.co.kr
Can Opus Genetics Inc. Regain Lost Ground This QuarterInsider Selling & Free Safe Entry Trade Signal Reports - newsyoung.net
Opus Genetics Inc. stock chart pattern explainedProduct Launch & Fast Entry Momentum Alerts - Newser
Quant Funds Rotate Into Opus Genetics Inc. StockTrade Risk Assessment & Safe Entry Momentum Stock Tips - 더경남뉴스
Why Opus Genetics Inc. stock attracts strong analyst attentionWeekly Loss Report & Verified Momentum Stock Ideas - Newser
How Opus Genetics Inc. stock reacts to Fed policy changes2025 Trade Ideas & Weekly Momentum Picks - Newser
Quantitative breakdown of Opus Genetics Inc. recent moveTrend Reversal & Precise Buy Zone Identification - Newser
How to integrate Opus Genetics Inc. into portfolio analysis toolsJuly 2025 Market Mood & High Return Trade Guides - Newser
Night Vision Disturbances Market to Experience Notable Growth - openPR.com
Night Vision Disturbances Market to Experience Notable Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris - The Globe and Mail
Opus Genetics’ OPGx-BEST1 cleared to enter clinic - BioWorld MedTech
FDA clears Opus Genetics' IND for BEST1 IRD gene therapy - Eyes On Eyecare
Opus Genetics announces FDA clearance of IND application for gene therapy candidate OPGx-BEST1 - Eyes On Eyecare
Promising Developments and Financial Stability Drive Buy Rating for Opus Genetics - TipRanks
Opus Genetics shares fall 4.17% intraday after FDA clearance of IND for OPGx-BEST1 gene therapy. - AInvest
Opus Genetics announces FDA clearance of IND application for OPGx-BEST1 - TipRanks
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1 - GlobeNewswire
First Gene Therapy IND for Best Disease: Opus Genetics' BEST1 Treatment Advances to Clinical Trials - Stock Titan
What high frequency data says about Opus Genetics Inc.Quarterly Earnings Summary & Reliable Price Breakout Signals - Newser
Opus Genetics reports Q2 EPS (12c) vs (30c) last year - MSN
Earnings visualization tools for Opus Genetics Inc.Earnings Performance Report & Real-Time Chart Breakout Alerts - Newser
Is Opus Genetics Inc. stock reversal real or fakePortfolio Update Summary & AI Forecasted Stock Moves - Newser
Sentiment analysis tools applied to Opus Genetics Inc.Short Setup & Free Technical Pattern Based Buy Signals - Newser
Automated trading signals detected on Opus Genetics Inc.Quarterly Trade Summary & Real-Time Sentiment Analysis - Newser
What to do if you’re stuck in Opus Genetics Inc.2025 Market Outlook & Capital Efficient Trade Techniques - Newser
How to monitor Opus Genetics Inc. with trend dashboardsWeekly Risk Report & Risk Controlled Daily Plans - Newser
Can a trend reversal in Opus Genetics Inc. lead to recovery2025 Top Gainers & High Conviction Buy Zone Alerts - Newser
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported Earnings, And Analysts Cut Their Target Price - ca.finance.yahoo.com
How liquid is Opus Genetics Inc. stockPortfolio Return Summary & High Yield Stock Recommendations - thegnnews.com
Volatility clustering patterns for Opus Genetics Inc.2025 Market Outlook & Fast Momentum Stock Entry Tips - Newser
Foundation Fighting Blindness, Inc. Net Worth (2025) - GuruFocus
Price momentum metrics for Opus Genetics Inc. explainedAnalyst Upgrade & Breakout Confirmation Alerts - Newser
Trendlines Converge — Decision Point for Opus Genetics Inc.2025 AllTime Highs & Daily Stock Momentum Reports - beatles.ru
Opus Genetics: Promising Clinical Trials and Strategic Partnerships Drive Buy Rating - TipRanks
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates - MSN
Park Ha Biological Technology Co., Ltd. shares fall 2.60% premarket after Opus Genetics reports positive clinical data and FDA designation. - AInvest
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Product Pipeline Updates - VisionMonday.com
Opus Genetics (IRD): Can the Launch of Claude Opus 4.1 Catalyze a Path to Profitability? - AInvest
0.98%
8.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):